Genprex completes Phase 1 dose escalation of Reqorsa + Tecentriq in ES-SCLC; Phase 2 opens

Genprex, Inc.

No dose-limiting toxicities observed; RP2D set at 0.12 mg/kg (highest dose tested).
Safety Review Committee approved opening Phase 2 expansion; enrollment has started.
Phase 2 will enroll ~50 patients at 10-15 U.S. sites; primary endpoint is 18-week PFS rate.
Futility analysis after 25th patient reaches 18 weeks of follow-up.
Acclaim-3 has FDA Fast Track and Orphan Drug designations for ES-SCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.